INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
70.46
+0.35 (+0.49%)
As of 11:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close70.11
Open70.03
Bid70.41 x 800
Ask70.47 x 800
Day's Range69.70 - 70.82
52 Week Range60.23 - 140.11
Volume784,348
Avg. Volume2,134,811
Market Cap14.934B
Beta1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateJul 31, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.71
Trade prices are not sourced from all markets
  • Benzinga2 days ago

    Benzinga's Bulls & Bears Of The Week: AT&T, Facebook, Intel, Netflix, Twitter And More

    Benzinga featured looks at many investor favorite stocks over the past week. Bullish calls included a number of leading tech stocks. Bearish calls included retailers and a newly minted merger. The new ...

  • Benzinga4 days ago

    Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade

    Incyte Corporation (NASDAQ: INCY )'s  pipeline  is devoid of any major catalysts in 2018, according to Morgan Stanley.  The Analyst Analyst Matthew Harrison downgraded Incyte from Overweight to Equal-weight ...

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wire5 days ago

    Incyte to Report Second Quarter Financial Results

    Incyte Corporation announced today that it has scheduled its second quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 31, 2018.

  • ACCESSWIRE6 days ago

    Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks

    WallStEquities.com observes the following stocks for today: Five Prime Therapeutics Inc. (NASDAQ: FPRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Immunomedics Inc. (NASDAQ: IMMU), and Incyte Corp. (NASDAQ: INCY). Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. rose 1.02%, ending Tuesday's trading session at $16.87.

  • Analysts’ Estimates and Recommendations for Incyte in July
    Market Realist7 days ago

    Analysts’ Estimates and Recommendations for Incyte in July

    Analysts expect Incyte Corporation (INCY) to report 45.2% growth in YoY (year-over-year) sales to $473.9 million during the second quarter, compared to $326.4 million during the second quarter of 2017. Incyte is expected to report net adjusted income of $56.1 million during the second quarter, compared to a net adjusted loss of $12.5 million during the second quarter of 2017. 

  • A Look at Incyte’s Product Portfolio in July
    Market Realist7 days ago

    A Look at Incyte’s Product Portfolio in July

    Incyte’s (INCY) product portfolio includes targeted therapies and immuno-therapies for oncology and non-oncology diseases. Incyte’s product portfolio includes 17 molecular targets and 19 clinical candidates. The chart below shows its revenues from collaborations since the first quarter of 2017.

  • Incyte’s Quarterly Revenue Stream
    Market Realist7 days ago

    Incyte’s Quarterly Revenue Stream

    Incyte Corporation (INCY) reported revenues of $382.3 million during the first quarter, a marginal decline in YoY (year-over-year) revenues compared to $384.1 million during the first quarter of 2017. These revenues include the product revenues from sales of Jakafi and Iclusig, royalty revenues from Jakavi and Olumiant, and milestone and contract revenues. The chart below compares the revenues for Incyte since the first quarter of 2017.

  • Incyte’s Quarterly Revenue Trends and Estimates
    Market Realist8 days ago

    Incyte’s Quarterly Revenue Trends and Estimates

    Incyte’s (INCY) consolidated revenues increased to $328.3 million in the first quarter compared to $384.1 million in the first quarter of 2017. The company reported a first-quarter net loss of $2.6 million, compared to net income of $29.1 million during the first quarter of 2017.

  • Incyte’s Valuations on July 6
    Market Realist8 days ago

    Incyte’s Valuations on July 6

    According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”

  • How Analysts Are Rating Puma Biotechnology in July
    Market Realist8 days ago

    How Analysts Are Rating Puma Biotechnology in July

    The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.

  • How Ionis Pharmaceuticals’ Valuation Compares
    Market Realist11 days ago

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.

  • Benzinga16 days ago

    Benzinga's Bulls & Bears Of The Week: Amazon, GE, Intel, T-Mobile And More

    Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included the old-school industrial that was just ousted from the Dow. Bearish calls included a leading semiconductor ...

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $454 million.

  • Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
    Zacks20 days ago

    Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

    The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

  • ACCESSWIRE20 days ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Incyte

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...

  • Barrons.com21 days ago

    After the Bell: Back From the Abyss

    Stocks recovered from a nerve-rattling start to the week, with the Dow Jones Industrial Average eking out a 0.1% gain. •...and review a downgrade for Incyte (INCY). The Dow Jones Industrial Average gained 30.31 points, or 0.12%, to 24283.11, while the  S&P 500 rose 5.99 points, or 0.22%, to 2723.06, and the Nasdaq Composite climbed 29.62 points, or 0.39%, to 7561.63.

  • Benzinga21 days ago

    Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility

    Incyte Corporation (NASDAQ: INCY) has suffered a series of setbacks in its clinical programs, with the company's epacadostat  failing to meet endpoints in a late-stage study for metastatic melanoma when evaluated in combination with Merck & Co., Inc. (NYSE: MRK)'s Keytruda. The Street overreacted to the recent clinical trial setbacks and shares should rebound to the mid-$70s, Abrahams said in a Tuesday note.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit22 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • ACCESSWIRE22 days ago

    Blog Exposure – Incyte's REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate of Ruxolitinib in Steroid-Refractory Acute GVHD

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want access to our free research report on Incyte Corp. (NASDAQ: INCY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INCY as the Company's latest news hit the wire. On June 21, 2018, the Company announced that its ongoing pivotal Phase-2 REACH1 trial, evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD), met its primary endpoint. Active-Investors.com is currently working on the research report for PolarityTE, Inc. (NASDAQ: COOL), which also belongs to the Healthcare sector as the Company Incyte.

  • Incyte (INCY) Announces Positive Results on Jakafi for GVHD
    Zacks25 days ago

    Incyte (INCY) Announces Positive Results on Jakafi for GVHD

    Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.

  • Business Wire26 days ago

    Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event

    Incyte Corporation (INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company’s growth opportunities and late-stage development portfolio. “The presentations today are intended to highlight our diversified development portfolio and its potential to accelerate our top-line growth in the near term,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “The success of the REACH1 study of Jakafi in steroid-refractory acute graft-versus-host disease (GVHD) announced earlier today is excellent news for patients, and also further reinforces the potential of JAK inhibition in GVHD and our development strategy to address this devastating disease.

  • Business Wire26 days ago

    Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease

    Incyte Corporation (INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28. In addition, the best overall response rate (BORR), the number of patients achieving a response at any time point during the study, was 73 percent (n=52/71).

  • Barrons.comlast month

    Former Incyte CEO Buys Slumping Nektar Shares

    Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...